非鳞状细胞喉癌:发病率、人口学特征、治疗模式及手术效果
基于美国国家癌症数据库(2004-2014)的回顾性分析纳入878例非鳞状细胞喉癌(占全部喉恶性肿瘤1.02%),按六种组织学亚型分析临床特征及手术对生存的影响;多因素分析显示手术与生存改善显著相关(HR 0.679,95%CI 0.472-0.976,P=0.036),具体术式对生存无影响。
要点
- 非鳞状细胞喉癌占全部喉恶性肿瘤约1.02%,共878例。
- 神经内分泌肿瘤远处转移率最高(已知M分期者中占19.1%),5年生存率最低(25.7%)。
- 多因素分析显示手术与生存改善显著相关(HR 0.679,95%CI 0.472-0.976,P=0.036)。
核心结论
- 约1%的喉恶性肿瘤为非鳞状细胞起源。
- 神经内分泌肿瘤初诊时远处转移率最高,预后最差。
- 多数非鳞状细胞喉癌患者接受了手术作为治疗方案的一部分。
- 多因素分析显示手术与生存改善显著相关(HR 0.679,95%CI 0.472-0.976,P=0.036)。
研究设计与样本
- 美国国家癌症数据库(2004-2014)的回顾性分析。
- 纳入成人非鳞状细胞喉癌患者,共878例,分为六种主要组织学亚型。
- 对非鳞状细胞患者获取描述性临床特征,并在该队列内行多因素回归分析手术对生存的影响。
- 证据等级:NA。
主要发现
- 非鳞状细胞喉癌878例,占全部喉恶性肿瘤的1.02%。
- 神经内分泌肿瘤和骨/软骨肉瘤为最大组,分别占37.02%和32.35%。
- 神经内分泌肿瘤远处转移比例更高,占已知临床M分期者的19.1%。
- 骨/软骨肉瘤5年生存率最高为90.4%,神经内分泌肿瘤5年生存率最低为25.7%。
- 在治疗患者中,骨/软骨肉瘤80.9%和轻微唾液腺肿瘤82.6%接受了手术作为治疗的一部分。
关键数值与推荐
- 手术与生存改善显著相关:HR 0.679(95%CI 0.472-0.976,P=0.036)。
- 具体手术方式(局部切除 vs 部分喉切除 vs 全喉切除)对生存无影响。
- 骨/软骨肉瘤5年生存率90.4%,神经内分泌肿瘤5年生存率25.7%。
- 神经内分泌肿瘤远处转移占已知临床M分期者的19.1%。
- 骨/软骨肉瘤80.9%、轻微唾液腺肿瘤82.6%接受手术作为治疗的一部分。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To analyze the incidence and clinical profile of nonsquamous cell (non-SCC) laryngeal carcinomas and to analyze the effect of surgery on survival. STUDY DESIGN: A retrospective analysis of the National Cancer Database (2004-2014). METHODS: Adult patients with non-SCC laryngeal cancers were divided into six major histological subtypes. A descriptive clinical profile was obtained for non-SCC patients, and multivariate regressions were performed to analyze the effect of surgery on survival within the non-SCC cohort. RESULTS: We identified 878 cases of non-SCC laryngeal cancers, representing 1.02% of all malignant laryngeal cancers. Neuroendocrine tumors and bone/cartilage sarcomas made up the largest groups (37.02% and 32.35%, respectively). Metastasis (M) was higher in neuroendocrine tumors, representing 19.1% of those with known clinical M stages. Of those treated, the majority of patients with bone/cartilage sarcomas (80.9%) and minor salivary gland tumors (82.6%) received surgery as part of their treatment. Survival varied significantly based upon histology, with bone/cartilage sarcomas having the highest 5-year survival at 90.4%, and neuroendocrine tumors exhibiting the poorest 5-year survival at 25.7%. Multivariate analyses found surgery to be significantly associated with improved survival (hazard ratio: 0.679; 95% confidence interval: 0.472-0.976; P = 0.036). The specific surgical method (i.e., local excision vs. partial vs. total laryngectomy) did not have any effect on survival. CONCLUSION: Approximately 1% of all malignant laryngeal cancers are non-SCC in origin. At presentation, neuroendocrine tumors have the highest rate of distant metastasis and have the worst prognosis of the non-SCC cancers. Most non-SCC patients received surgery as part of their treatment regimen. LEVEL OF EVIDENCE: NA. Laryngoscope, 129:2496-2505, 2019.
引用
- Torabi SJ, Cheraghlou S, Kasle DA, et al. Nonsquamous cell laryngeal cancers: Incidence, demographics, care patterns, and effect of surgery. Laryngoscope. 2019. PMID: 30632157. doi:10.1002/lary.27785
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。